Expert Highlights
Watch as experts George L. Bakris, MD, Rajiv Agarwal, MD, and Janet McGill, MD, discuss additional clinical pearls on DKD progression and the emerging role of novel non-steroidal MRAs for the treatment of DKD
| Interview #1 Evaluating the Risk for DKD ProgressionWatch the experts share some highlights including: - Early recognition and screening for DKD
- Monitoring kidney function
- Risk factors for DKD progression
|
| Interview #2 The Rationale for Non-Steroidal MRAs in DKDWatch the experts share some highlights including: - Differentiating between steroidal and non-steroidal MRAs
- Adverse events and limitations with steroidal MRAs in DKD
- Advantages of finerenone in DKD
- The overview of kidney results of the FIDELIO trial
|
| Interview #3 The Cardiovascular Benefits of FinerenoneWatch the experts share some highlights including: - The interplay between the kidney and heart
- CVD benefits of finerenone: analysis from the FIDELIO trial and ongoing CVD studies with finerenone
- How does finerenone fit within the context of SGLT-2is
|
| Interview #4 Finerenone: Putting the Data Into ContextWatch the experts share some highlights including: - Finerenone in the context of existing treatments
- Clinical pearls for incorporating finerenone to the DKD treatment armamentarium in the near future
|